MedPath

Effects of salsalate on glucose metabolism

Phase 3
Conditions
Diabetes Mellitus.
Non-insulin-dependent diabetes mellitus
Registration Number
IRCT138709011465N1
Lead Sponsor
Isfahan Endocrine and Metabolism Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
180
Inclusion Criteria

HbA1c>=5% and BS<250 and (FBS>=100mg/dl or BS>=140mg/dl in OGTT) Exclusion criteria: Type 1 DM or past history of DKA, pregnancy/lactation, surgery within 1 month before the trial, known diagnosed malignancy, confirmed peptic ulcer or GI bleeding, diagnosed heart failure (function class 3 or 4), clinical ACS, CVA, TIA, revascularization within 6 month prior to study, uncontrolled hypertension (systolic BP>150 mmHg or diastolic BP>100 mmHg with full dose of 3 drugs) , history of drug abuse or alcohol consumption, history of active hepatitis , psychological disorders , previous allergy to aspirin or NSAIDS , continuous use of NSAIDS , Warfarin, Clopidogrel, Corticosteroid, Macroalbuminuria, chronic tinnitus, Hb<12 mg/dl in men and Hb<10 in women , platelets<100000, Triglyceride>500 mg/dl , serum creatinine more than 1.4 in women and more than 1.5 in men or GFR<60.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fasting blood glucose. Timepoint: weeks ( 0, 4, 8, 12). Method of measurement: Enzymatic.
Secondary Outcome Measures
NameTimeMethod
Insulin resistance. Timepoint: weeks ( 0 , 4 , 8 , 12). Method of measurement: (plasma insulin)(plasma glucose)/22.5=HOMA-IR.
© Copyright 2025. All Rights Reserved by MedPath